{"id":2911,"date":"2026-10-26T19:06:11","date_gmt":"2026-10-26T19:06:11","guid":{"rendered":"https:\/\/admarebio.com\/news-events\/news-insights\/"},"modified":"2026-11-02T15:17:37","modified_gmt":"2026-11-02T15:17:37","slug":"specific-biologics","status":"publish","type":"post","link":"https:\/\/admarebio.com\/news-events\/news-insights\/specific-biologics\/","title":{"rendered":"Specific Biologics"},"content":{"rendered":"\n<h3 class=\"wp-block-heading\">Company description: <\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Toronto-based biotechnology company developing a next generation gene editing platform for the treatment of severe neurological and neuromuscular genetic diseases such as amyotrophic lateral sclerosis (ALS) and Huntington\u2019s disease.<\/p>\n\n\n\n<ul style=\"margin-right:var(--wp--preset--spacing--10);margin-left:var(--wp--preset--spacing--10)\" class=\"wp-block-list\">\n<li>Technology: Platform<\/li>\n\n\n\n<li>Modality: Gene therapy delivered = LNP-mRNA or single AAV<\/li>\n\n\n\n<li>Stage: Preclinical<\/li>\n<\/ul>\n\n\n\n<div style=\"height:19px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h3 class=\"wp-block-heading\">Why it matters (The breaktrough idea):<\/h3>\n\n\n\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-794e3cfa wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<p class=\"wp-block-paragraph\">Specific Biologics is developing a next generation gene editing technology called&nbsp; Dualase \u00ae that uses a two-site mechanism to make precise genetic corrections to disease-causing DNA while minimizing unintended edits. This novel approach is designed to overcome important safety and efficacy limitations of existing gene editing technologies.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The platform has the potential to address a wide range of genetic diseases. Specific Biologics is initially focused on diseases caused by abnormal DNA repeat expansions, with a lead program targeting a genetic form of amyotrophic lateral sclerosis (ALS)<\/p>\n\n\n\n<div class=\"wp-block-buttons is-layout-flex wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button\"><a class=\"wp-block-button__link wp-element-button\" href=\"https:\/\/admarebio.com\/en\/building-companies\/portfolio\/\">See our other portfolio companies<\/a><\/div>\n<\/div>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<figure class=\"wp-block-image size-full has-custom-border\"><img loading=\"lazy\" decoding=\"async\" width=\"719\" height=\"379\" src=\"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/10\/specific-biologics-2.jpg\" alt=\"\" class=\"has-border-color has-admare-blue-border-color wp-image-2899\" style=\"border-width:3px;border-top-left-radius:48px;border-top-right-radius:48px;border-bottom-left-radius:48px;border-bottom-right-radius:48px\"\/><\/figure>\n<\/div>\n<\/div>\n\n\n\n<div style=\"height:19px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h3 class=\"wp-block-heading\">adMare&#8217;s role: <\/h3>\n\n\n\n<div class=\"wp-block-group is-style-default has-border-color has-cobalt-border-color has-glacier-background-color has-background wp-elements-1 is-layout-constrained wp-container-core-group-is-layout-d4c2d7a2 wp-block-group-is-layout-constrained\" style=\"border-width:2px;border-top-left-radius:10px;border-top-right-radius:10px;border-bottom-left-radius:10px;border-bottom-right-radius:10px;padding-top:0;padding-right:0;padding-bottom:0;padding-left:0\">\n<div class=\"wp-block-group is-layout-constrained wp-block-group-is-layout-constrained\">\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<h2 class=\"wp-block-heading has-text-align-center has-large-font-size\" style=\"font-weight:700;line-height:1.2\"><strong style=\"font-weight: bold;\">Validation<\/strong><\/h2>\n<\/div>\n\n\n\n<div class=\"wp-block-group has-indigo-color has-text-color has-link-color wp-elements-2 is-content-justification-left is-layout-constrained wp-container-core-group-is-layout-8f7a88a5 wp-block-group-is-layout-constrained\" style=\"margin-top:0;margin-bottom:0;padding-top:var(--wp--preset--spacing--40);padding-right:var(--wp--preset--spacing--40);padding-bottom:var(--wp--preset--spacing--40);padding-left:var(--wp--preset--spacing--40)\">\n<ul class=\"wp-block-list\">\n<li><strong>Academic research translation:<\/strong> Specific Biologics\u2019 Dualase\u00ae gene editing platform is based on breakthrough research by Dr. David Edgell at Western University.<br><\/li>\n\n\n\n<li><strong>Scientific and commercial validation:<\/strong> adMare worked with the founding team to assess the differentiating aspects and commercial potential of the Dualase\u00ae technology. This led to the development of&nbsp; a focused R&amp;D plandesigned to validate the breadth of this technology platform across a selected number of promising disease targets.<\/li>\n<\/ul>\n<\/div>\n<\/div>\n\n\n\n<div class=\"wp-block-group is-style-default has-border-color has-cobalt-border-color has-glacier-background-color has-background wp-elements-3 is-layout-constrained wp-container-core-group-is-layout-d4c2d7a2 wp-block-group-is-layout-constrained\" style=\"border-width:2px;border-top-left-radius:10px;border-top-right-radius:10px;border-bottom-left-radius:10px;border-bottom-right-radius:10px;padding-top:0;padding-right:0;padding-bottom:0;padding-left:0\">\n<div class=\"wp-block-group is-layout-constrained wp-block-group-is-layout-constrained\">\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<h2 class=\"wp-block-heading has-text-align-center has-large-font-size\" style=\"font-weight:700;line-height:1.2\"><strong style=\"font-weight: bold;\">Incubation<\/strong><\/h2>\n<\/div>\n\n\n\n<div class=\"wp-block-group has-indigo-color has-text-color has-link-color wp-elements-4 is-content-justification-left is-layout-constrained wp-container-core-group-is-layout-8f7a88a5 wp-block-group-is-layout-constrained\" style=\"margin-top:0;margin-bottom:0;padding-top:var(--wp--preset--spacing--40);padding-right:var(--wp--preset--spacing--40);padding-bottom:var(--wp--preset--spacing--40);padding-left:var(--wp--preset--spacing--40)\">\n<ul class=\"wp-block-list\">\n<li><strong>Seed investment and syndication:<\/strong> Early-on, adMare attracted Lumira Ventures to this investment opportunity, and both firms co-led Specific Biologics\u2019 Seed financing , providing the capital needed to execute the R&amp;D validation plan.<br><\/li>\n\n\n\n<li><strong>R&amp;D execution and de-risking:<\/strong> Following seed financing, adMare collaborated closely with the company in the execution of this&nbsp;multi-year validation program that evaluated six therapeutic targets using in vitro assays and animal models. This work helped identify ALS as the company\u2019s lead program and generated critical proof-of-concept and efficacy data needed to attract Series A investors.<br><\/li>\n\n\n\n<li><strong>Operational support:<\/strong> adMare provided scientific expertise, project management, strategic guidance and governance support as Specific Biologics advanced its platform and built internal capabilities.<br><\/li>\n\n\n\n<li><strong>Talent development:<\/strong> Through adMare&#8217;s ASCEND postdoctoral fellowship program, Specific Biologics was able to augment its scientific team with highly qualified talent to help advance key R&amp;D priorities. adMare provided 50% of the Fellow&#8217;s compensation, as well as recruitment, onboarding, and leadership development support, helping the company build capacity and conserve capital while advancing its development programs and contributing to Canada\u2019s next generation of life sciences talent.<\/li>\n<\/ul>\n<\/div>\n<\/div>\n\n\n\n<div style=\"height:19px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<div class=\"wp-block-group is-style-default has-border-color has-cobalt-border-color has-glacier-background-color has-background wp-elements-5 is-layout-constrained wp-container-core-group-is-layout-d4c2d7a2 wp-block-group-is-layout-constrained\" style=\"border-width:2px;border-top-left-radius:10px;border-top-right-radius:10px;border-bottom-left-radius:10px;border-bottom-right-radius:10px;padding-top:0;padding-right:0;padding-bottom:0;padding-left:0\">\n<div class=\"wp-block-group is-layout-constrained wp-block-group-is-layout-constrained\">\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<h2 class=\"wp-block-heading has-text-align-center has-large-font-size\" style=\"font-weight:700;line-height:1.2\"><strong style=\"font-weight: bold;\">Acceleration<\/strong><\/h2>\n<\/div>\n\n\n\n<div class=\"wp-block-group has-indigo-color has-text-color has-link-color wp-elements-6 is-content-justification-left is-layout-constrained wp-container-core-group-is-layout-8f7a88a5 wp-block-group-is-layout-constrained\" style=\"margin-top:0;margin-bottom:0;padding-top:var(--wp--preset--spacing--40);padding-right:var(--wp--preset--spacing--40);padding-bottom:var(--wp--preset--spacing--40);padding-left:var(--wp--preset--spacing--40)\">\n<ul class=\"wp-block-list\">\n<li><strong>Series A investment and syndication:<\/strong> adMare participated in Specific Biologics\u2019 US $35 million Series A financing (CAD $49 million), demonstrating continued confidence in the company and helping catalyze a strong investment syndicate. The round strengthened Canadian ownership with \u00a0continued investment from Lumira Ventures along withnew domestic investment from Genesys Capital, BDC Life Sciences Venture Fund, and Seido Capital. \u00a0 Led by U.S. investor Hatteras Venture Partners the round also \u00a0attracted international capital and expertise. \u00a0\u00a0<\/li>\n<\/ul>\n<\/div>\n<\/div>\n\n\n\n<h3 class=\"wp-block-heading\">What&#8217;s next?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The Series A financing will support the safety, manufacturing, and regulatory work required to advance Specific Biologics\u2019 lead ALS program toward a first-in-human clinical trial. The company will also continue pursuing partnerships and advancing additional applications of the Dualase\u00ae platform, creating opportunities to address other serious genetic diseases.&nbsp;<\/p>\n\n\n\n<div style=\"height:19px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h3 class=\"wp-block-heading\">Benefit to Canada?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">adMare helped transform a breakthrough technology originating at Western University into an investment-ready Canadian biotechnology company. By combining domestic capital with scientific, operational and talent support, adMare helped Specific Biologics generate the evidence needed to attract significant Canadian and international investment.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The company\u2019s progress demonstrates how targeted early-stage support can create highly skilled jobs, strengthen Canadian expertise in next-generation gene editing, and keep more intellectual property and economic value rooted in Canada. The Series A also represents one of the first investments by BDC\u2019s new Life Sciences Fund, highlighting the importance of adMare\u2019s role in building a strong pipeline of investable Canadian companies ready for new sources of domestic growth capital.\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Company description: Toronto-based biotechnology company developing a next generation gene editing platform for the treatment of severe neurological and neuromuscular genetic diseases such as amyotrophic lateral sclerosis (ALS) and Huntington\u2019s [&hellip;]<\/p>\n","protected":false},"author":8,"featured_media":2899,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[153],"tags":[],"company":[80],"class_list":["post-2911","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-case-studies"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Specific Biologics | adMare<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/admarebio.com\/en\/news-events\/news-insights\/specific-biologics\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Specific Biologics | adMare\" \/>\n<meta property=\"og:description\" content=\"Company description: Toronto-based biotechnology company developing a next generation gene editing platform for the treatment of severe neurological and neuromuscular genetic diseases such as amyotrophic lateral sclerosis (ALS) and Huntington\u2019s [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/admarebio.com\/news-events\/news-insights\/specific-biologics\/\" \/>\n<meta property=\"og:site_name\" content=\"adMare\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-26T19:06:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-11-02T15:17:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/10\/specific-biologics-2.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"719\" \/>\n\t<meta property=\"og:image:height\" content=\"379\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Alexis Bouffioux\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Alexis Bouffioux\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/specific-biologics\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/specific-biologics\\\/\"},\"author\":{\"name\":\"Alexis Bouffioux\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#\\\/schema\\\/person\\\/87e6ba6ef08826d003854731e1971add\"},\"headline\":\"Specific Biologics\",\"datePublished\":\"2026-10-26T19:06:11+00:00\",\"dateModified\":\"2026-11-02T15:17:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/specific-biologics\\\/\"},\"wordCount\":648,\"publisher\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/specific-biologics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/specific-biologics-2.jpg\",\"articleSection\":[\"Case Studies\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/specific-biologics\\\/\",\"url\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/specific-biologics\\\/\",\"name\":\"Specific Biologics | adMare\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/specific-biologics\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/specific-biologics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/specific-biologics-2.jpg\",\"datePublished\":\"2026-10-26T19:06:11+00:00\",\"dateModified\":\"2026-11-02T15:17:37+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/specific-biologics\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/specific-biologics\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/specific-biologics\\\/#primaryimage\",\"url\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/specific-biologics-2.jpg\",\"contentUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/specific-biologics-2.jpg\",\"width\":719,\"height\":379},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/specific-biologics\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/admarebio.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News &#038; Events\",\"item\":\"https:\\\/\\\/admarebio.com\\\/en\\\/news-events\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"News &#038; Insights\",\"item\":\"https:\\\/\\\/admarebio.com\\\/en\\\/news-events\\\/news-insights\\\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Specific Biologics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/admarebio.com\\\/en\\\/\",\"name\":\"adMare\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/admarebio.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#organization\",\"name\":\"adMare\",\"url\":\"https:\\\/\\\/admarebio.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/Logo-light.svg\",\"contentUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/Logo-light.svg\",\"width\":915,\"height\":337,\"caption\":\"adMare\"},\"image\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#\\\/schema\\\/person\\\/87e6ba6ef08826d003854731e1971add\",\"name\":\"Alexis Bouffioux\",\"url\":\"#\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Specific Biologics | adMare","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/admarebio.com\/en\/news-events\/news-insights\/specific-biologics\/","og_locale":"en_US","og_type":"article","og_title":"Specific Biologics | adMare","og_description":"Company description: Toronto-based biotechnology company developing a next generation gene editing platform for the treatment of severe neurological and neuromuscular genetic diseases such as amyotrophic lateral sclerosis (ALS) and Huntington\u2019s [&hellip;]","og_url":"https:\/\/admarebio.com\/news-events\/news-insights\/specific-biologics\/","og_site_name":"adMare","article_published_time":"2026-10-26T19:06:11+00:00","article_modified_time":"2026-11-02T15:17:37+00:00","og_image":[{"width":719,"height":379,"url":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/10\/specific-biologics-2.jpg","type":"image\/jpeg"}],"author":"Alexis Bouffioux","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Alexis Bouffioux","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/admarebio.com\/news-events\/news-insights\/specific-biologics\/#article","isPartOf":{"@id":"https:\/\/admarebio.com\/news-events\/news-insights\/specific-biologics\/"},"author":{"name":"Alexis Bouffioux","@id":"https:\/\/admarebio.com\/en\/#\/schema\/person\/87e6ba6ef08826d003854731e1971add"},"headline":"Specific Biologics","datePublished":"2026-10-26T19:06:11+00:00","dateModified":"2026-11-02T15:17:37+00:00","mainEntityOfPage":{"@id":"https:\/\/admarebio.com\/news-events\/news-insights\/specific-biologics\/"},"wordCount":648,"publisher":{"@id":"https:\/\/admarebio.com\/en\/#organization"},"image":{"@id":"https:\/\/admarebio.com\/news-events\/news-insights\/specific-biologics\/#primaryimage"},"thumbnailUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/10\/specific-biologics-2.jpg","articleSection":["Case Studies"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/admarebio.com\/news-events\/news-insights\/specific-biologics\/","url":"https:\/\/admarebio.com\/news-events\/news-insights\/specific-biologics\/","name":"Specific Biologics | adMare","isPartOf":{"@id":"https:\/\/admarebio.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/admarebio.com\/news-events\/news-insights\/specific-biologics\/#primaryimage"},"image":{"@id":"https:\/\/admarebio.com\/news-events\/news-insights\/specific-biologics\/#primaryimage"},"thumbnailUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/10\/specific-biologics-2.jpg","datePublished":"2026-10-26T19:06:11+00:00","dateModified":"2026-11-02T15:17:37+00:00","breadcrumb":{"@id":"https:\/\/admarebio.com\/news-events\/news-insights\/specific-biologics\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/admarebio.com\/news-events\/news-insights\/specific-biologics\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/admarebio.com\/news-events\/news-insights\/specific-biologics\/#primaryimage","url":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/10\/specific-biologics-2.jpg","contentUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/10\/specific-biologics-2.jpg","width":719,"height":379},{"@type":"BreadcrumbList","@id":"https:\/\/admarebio.com\/news-events\/news-insights\/specific-biologics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/admarebio.com\/en\/"},{"@type":"ListItem","position":2,"name":"News &#038; Events","item":"https:\/\/admarebio.com\/en\/news-events\/"},{"@type":"ListItem","position":3,"name":"News &#038; Insights","item":"https:\/\/admarebio.com\/en\/news-events\/news-insights\/"},{"@type":"ListItem","position":4,"name":"Specific Biologics"}]},{"@type":"WebSite","@id":"https:\/\/admarebio.com\/en\/#website","url":"https:\/\/admarebio.com\/en\/","name":"adMare","description":"","publisher":{"@id":"https:\/\/admarebio.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/admarebio.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/admarebio.com\/en\/#organization","name":"adMare","url":"https:\/\/admarebio.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/admarebio.com\/en\/#\/schema\/logo\/image\/","url":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/03\/Logo-light.svg","contentUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/03\/Logo-light.svg","width":915,"height":337,"caption":"adMare"},"image":{"@id":"https:\/\/admarebio.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/admarebio.com\/en\/#\/schema\/person\/87e6ba6ef08826d003854731e1971add","name":"Alexis Bouffioux","url":"#"}]}},"_links":{"self":[{"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/posts\/2911","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/comments?post=2911"}],"version-history":[{"count":19,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/posts\/2911\/revisions"}],"predecessor-version":[{"id":2951,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/posts\/2911\/revisions\/2951"}],"wp:attachment":[{"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/media?parent=2911"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/categories?post=2911"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/tags?post=2911"},{"taxonomy":"company","embeddable":true,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/company?post=2911"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}